German Pharma Industry Warns Drug Price Caps Could Undermine Research Investment
Companies including Bayer and other major pharmaceutical firms have warned that proposed drug pricing restrictions could weaken Germany’s attractiveness for research and development. Industry representatives argue that stricter price controls may reduce long-term investment in new medicines.